Latest From Servier SA
CAR-T therapies from Janssen, Celgene and others will get a lot of attention at the annual hematology meeting, including candidates with novel constructs and targets.
The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH inhibitor market in anemia, while Takeda and Meiji Seika see other important approvals and the first biosimilar teriparatide receives a nod.
Liposomal chemotherapy drug Onivyde achieved a 44% response rate in second-line small cell lung cancer patients, providing preliminary validation of its ability to improve outcomes in the hard-to-treat disease.
Private Company Edition: ARM's Q2 report shows a 38% decline in financings, but venture capital and upfront fees from deals were robust. Also, Servier raises $405m in the US, Frequency closes a $62m series C and VenatoRx accesses US government cash.
- Therapeutic Areas
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- Servier SA
- Senior Management
Olivier Laureau, CEO
Emmanuel Canet, Sr. EVP, R&D
- Contact Info
Phone: (33) 55 72 60 00
35 rue de Verdun
Suresnes Cedex, 92284
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.